Antidiabetics Market Size By Product (Insulin [Rapid Acting, Long Acting, Premixed Insulin, Short Acting, Intermediate Acting], Drug Class [Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolidinedione]), By Patient Population (Pediatric, Adult, Geriatric), By Route Of Administration (Insulin Syringe/Insulin Pen, Insulin Pump, Intravenous Infusion, Oral) Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 – 2024

Published Date: Oct 2018  |  Report ID: GMI504  |  Authors: Sumant Ugalmugle

Report Format: PDF   |   Pages: 170   |   Base Year: 2017

Summary Table of Contents Industry Coverage Methodology

Industry Trends

Antidiabetics Market size was valued at USD 54.6 billion in 2017 and is expected to witness growth of over 10.6% CAGR from 2018 to 2024.

Antidiabetics Market

Get more details on this report - Request Free Sample PDF

Growing pervasiveness of diabetes worldwide will spur global antidiabetics market growth over the forecast timeframe. According to World Health Organization, in 2014, 422 million people suffered from diabetes mellitus, estimated to become the seventh death-leading cause by 2030. Thus, rising prevalence of the disease will lead to high adoption of antidiabetic drugs to control blood sugar as well as control disease complications. Moreover, accelerating number of obese/overweight people, pursuing unhealthy lifestyle habits is significantly increasing the risk of suffering from diabetes. Growing incidence of diabetes can be attributed to increasing obese population, thereby augmenting demand for antidiabetics in coming years.

Increasing focus on research activities for development of antidiabetics will stimulate antidiabetics business growth during the upcoming years. Adverse events and need for more effective drugs are leading firms to invest more into antidiabetic drugs and antidiabetics delivering devices. For instance, Novo Nordisk is investing heavily on its pipeline drug, Ozempic, for type 2 diabetes in adults. In addition, need for development of affordable drugs, especially in emerging nations will result into huge pipeline portfolio of firms, further offering lucrative industry growth opportunities in the foreseeable future.

Antidiabetics Market Report Coverage
Report Coverage Details
Base Year: 2017 Market Size in 2017: 54.6 Billion (USD)
Historical Data for: 2013 to 2017 Forecast Period: 2018 to 2024
Forecast Period 2018 to 2024 CAGR: 10.6% 2024 Value Projection: 110 Billion (USD)
Pages: 170 Tables, Charts & Figures: 144
Geographies covered (15): U.S., Canada, Germany, UK, France, Spain, Italy, China, Japan, India, Australia, Brazil, Mexico, South Africa, Saudi Arabia
Segments covered: Product, Route Of Administration and Region
Companies covered (14): AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Halozyme Therapeutics, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Novo Nordisk, Oramed Pharmaceuticals Inc., Pfizer, Sanofi, Takeda Pharmaceutical
Growth Drivers:
  • Strong product pipeline of antidiabetics
  • Globally rising prevalence of diabetes
  • Increasing prevalence of lifestyle induced disorders such as obesity
Pitfalls & Challenges:
  • Prohibitive cost of insulin

Request 15% Free Customization on this Report

Antidiabetics Market, By Product

Insulin product segment is forecasted to progress at 12.3% CAGR over the projected period. With expanding patient population majorly suffering from type 2 diabetes, the need to administer insulin therapy will grow in the forthcoming years. Insulin is also used in combination with several oral drugs for better control of blood glucose. In addition, insulin also needs to be externally injected to patients with type 1 diabetes, that should impel segmental growth in coming period. Among several types of insulin, rapid acting analog insulin will show fastest growth over the forecast period.

Drug class product segment held 45.7% market share in 2017. DPP-IV drug class accounted for the largest revenue size in 2017 and will witness similar trend over the coming years. DPP-IV when combined with other antidiabetic agents are known to show positive effect on glucose control. These drugs show neutral effect on weight that further favours segmental growth. Development of new antidiabetic drugs including DPP-IV will boost segment growth in upcoming years.

Germany Antidiabetics Market Size By Product

Get more details on this report - Request Free Sample PDF

Antidiabetics Market, By Patient Population

Adult patient population segment accounted for largest market share of 51.0% in 2017. With increasing risk factors such as age, obesity, lack of physical activity and rising consumption of carbohydrate-rich food among adult age groups has considerable effect on development of diabetes. According to a recent study, majority of adults in comparison to other age groups are suffering from type 2 diabetes. According to the International Diabetes Federation (IDF), in 2017, 1 in 11 adults were suffering from diabetes across the globe. Similarly, consumption of antidiabetic drugs has increased considerably in Europe during recent years. Such factors will impel adults segmental share in forthcoming period.

Pediatric patient population segment will grow at 11.4% CAGR over the projected period. Number of diabetes cases among paediatric population are growing rapidly. Along with type 1 diabetes, that is majorly found in children, paediatric population suffering from type 2 diabetes is also significantly escalating. Additionally, implementation of several children programs for diabetes will support antidiabetics market growth over the foreseeable future.

Antidiabetics Market, By Route of Administration

Oral antidiabetics market contributed to largest revenue size of USD 39,714.7 million in 2017. Oral hypoglycaemics are widely used for T2DM patients. Newer drugs are largely being created by firms to be given through oral route for more efficacy as well as to overcome limitations of non-oral medications. Patients with T2DM are required to adopt oral medication within a couple of years post-diagnosis. Also, oral antidiabetics improve beta cell function indirectly while reducing glucotoxicity. Above benefits will assist oral antidiabetics segment growth during the forecast period.

Insulin pumps market will record highest CAGR of 11.3% during the projection timeframe. Insulin pump usage is recommended in patients having high resistance to insulin and weak glycaemic control. Insulin pumps prevent administration of multiple injections along with delivering high efficacy should escalate the customer preference. Availability of reimbursement in some countries will further accelerate demand for insulin pumps in the coming years.

Antidiabetics Market, By Region

U.S. antidiabetics market held largest market share of 87.5% of North America antidiabetics market in 2017. High growth is attributable to elevating cases of diabetes along with robustly rising obese population. Majority of the adult population affected by diabetes mellitus are overweight or obese. Many firms across the U.S. are emphasizing on innovative diabetes medications. Also, growing awareness among the American population regarding diagnosis and treatment of target disease will boost demand for antidiabetics in future.

China antidiabetics market will foresee lucrative growth at 14.6% CAGR during the forecast years. Rising geriatric pool will significantly contribute to growing demand for antidiabetics across the country. Age being one of the major risk factors for the disease, China has one of the largest patient pools with diagnosed diabetes. With ever-increasing elderly population along with growing R&D activities, Chinese antidiabetics business will continue to grow robustly in forthcoming years.

Europe Antidiabetics Market By Country

Get more details on this report - Request Free Sample PDF

Competitive Market Share

Few of the prominent industry players operating in global antidiabetics market include Novo Nordisk, Sanofi, Eli Lilly, Merck and Boehringer Ingelheim. Key players are implementing product innovations along with collaborations to reap greater profits in the market. For instance, in October 2018, Eli Lilly partnered with Lupin to distribute Eli Lilly’s diabetes injections. The strategy is aimed at expanding company’s medications across India.

Antidiabetics Industry Background  

Antidiabetics industry witnessed the first commercially available medication in 1936 known as PZI (protamine zinc insulin). Nordisk followed the first drug development when NPH (neutral protamine Hagedorn) was released in Denmark by the company. Further innovations were made subsequently including lente series of insulin that was trailed by first approved rapid-acting human insulin in 1996. Recently, firms are focusing on breakthroughs in antidiabetics market that will further progress the innovations in antidiabetic drugs. In addition, expanding patient population across the world will largely contribute to rise in demand for antidiabetics, thereby augmenting antidiabetics industry growth in the foreseeable future.

Buy NowImmediate delivery available

Single User: $5,150 Access to only 1 person; cannot be shared; cannot be printed
Multi User: $7,150 Access for 2 to 5 users only within same department of one company
Enterprise User: $9,150 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

GMIPulse Subscription Trial

Take a free trial of GMIPuse, our report store; designed to provide clients a range of market research services, all on a single platform.

Start Your Free Trial

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X